Furthermore, targeting of tumor vessels using anti-VEGFR-2 antibody with lower doses inducing vascular normalization, but not high doses, resulted in reprograming the immune suppressive microenvironment toward the potentiation of immune active status [21]. This evidence concerns the gene KDR and neoplasm.